Merck announces research collaboration with Domain Therapeutics in immuno-oncology

MerckMerck, a leading science and technology company, today announced it has entered into a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents. This collaboration strengthens the combination strategy in immuno-oncology, and underscores Merck's science-driven approach to discovering and developing novel compounds through both internal capabilities and external collaborations.

"This new generation of adenosine receptor antagonists are an important addition to our immuno-oncology pipeline," said Laszlo Radvanyi, Senior Vice President, Head of Research in Immuno-Oncology at the biopharma business of Merck. "We plan to explore the promise of adenosine receptor antagonists and develop novel compounds to potentially use in new combination immunotherapies for cancer." Adenosine receptor antagonists are small molecules thought to slow tumor progression and improve the response to combination immunotherapies by inhibiting adenosine - a compound generated by cancer cells that inhibits anti-tumor responses by binding to T cells.

The agreement will involve a close collaboration between Merck and Domain Therapeutics to develop and test new agents targeting key adenosine receptors. Merck will support research activities and gain worldwide rights to Domain Therapeutics’ next generation of adenosine receptor inhibitors.

"With its growing portfolio of immuno-oncology agents, Merck is the ideal partner to develop our adenosine programs," said Pascal Neuville, CEO, Domain Therapeutics. "As a strong collaborator with a leading investigational checkpoint inhibitor, we are confident that through Merck, our programs will progress rapidly."

Merck is committed to exploring an array of targets, and taking creative scientific approaches to developing novel therapies for hard-to-treat cancers. The strength of Merck's promising oncology development program and growing presence in the immunotherapy space demonstrates how the company is re-imagining the way cancer care is delivered.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Nearly 1 in 3 drugs found to have safety concerns …

How often are safety concerns raised about a drug after it's been approved by the FDA? Nicholas Downing, MD, of the Department of Medicine at Brigham and Women's Hospital...

Read more

Alzheimer's experts call for changes in FDA drug a…

Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, "Single Endpoint for New Drug Approvals for Alzheimer's Disease," ur...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]